-
Benzinga’s Top Pre-Market NASDAQ Gainers (DTPI, FMCN, AVII, VECO)
Tuesday, August 24, 2010 - 8:35am | 176Diamond Management & Technology Consultants Inc (NASDAQ: DTPI) rose 30.40% to $12.44 in the pre-market session. PricewaterhouseCoopers LLP has agreed to buy all of the outstanding common shares of DTPI for $378 million or $12.50 per share in cash, representing a premium of 31% to DTPI's closing...
-
The Architecture Billing Index (Leading Indicator) Improves in July and In 5 Out of the Last 6 Months
Thursday, August 19, 2010 - 3:54pm | 418The American Institute of Architects (AIA) released its monthly Architecture Billings Index (ABI) yesterday for July, which improved to 47.9 last month compared to June, and marked the fifth monthly increase during the last six months. Also, the July reading was almost the highest index level for...
-
PBIO: Q2 Better Than Expected; Price Target Raised to $5.00 - Analyst Blog
Thursday, August 19, 2010 - 1:34pm | 378On August 17, 2010, Pressure BioSciences, Inc. (PBIO) reported strong financial results for the three month period ended June 30 2010. Total revenue for 2Q10 was $402,104, compared to $270,381 for the comparable period in 2009, a 49% increase. Revenue from the sale of PCT products and services...
-
Hologic Stays Neutral - Analyst Blog
Thursday, August 19, 2010 - 12:04pm | 556We recently reiterated our Neutral recommendation on Hologic (HOLX) with a target price of $16.00. Hologic operates through four segments–Breasts Health, Diagnostics, GYN (Gynecology) Surgical, and Skeletal Health which contributed 45%, 33%, 17% and 5%, respectively, to total revenues during the...
-
2H:10 Milestones In Drug Discovery (ARNA, VRTX, REGN, EXEL)
Wednesday, August 18, 2010 - 11:28am | 276Piper Jaffray is out with an industry note, where it introduces well financed biotech companies that are preparing to launch potential blockbuster drugs. These drugs are expected to face value inflection points and outperform the broader market over the next 12-24 months. In the report, analysts...
-
Oppenheimer’s Architecture Billing index Update (ESSX, MGRC, RBA)
Wednesday, August 18, 2010 - 9:13am | 298Oppenheimer is out with a research report this morning, where it takes a look at the recently released July Architecture Billings Index (ABI) data and what it means for its coverage space. The AIA's Architecture Billings Index (ABI) increased 1.9 points to 47.9 in July from 46.0 in June. While...
-
Benzinga’s Top Pre-Market NASDAQ Losers (MNKD, MAIN, NVAX, QGEN)
Tuesday, August 17, 2010 - 8:36am | 137MannKind Corporation (NASDAQ: MNKD) dipped 7.04% to $6.34 in the pre-market session. MNKD has announced the proposed offering of about 8,000,000 shares of its common stock. Main Street Capital Corporation (NASDAQ: MAIN) lost 3.71% to $15.04 in the pre-market session. Analysts at Ladenburg Thalmann...
-
Pressure BioSciences Offers Unique Technology - Analyst Blog
Monday, August 16, 2010 - 7:06pm | 901Pressure BioSciences Inc. (NASDAQ: PBIO) is a life sciences company engaged in the research, development and commercialization of a novel, enabling platform technology called pressure cycling technology (PCT). The company’s technology platform is based on high hydrostatic pressure technology, a...
-
Fast Money Picks For August 17th (PRXL, MO, GENZ, TJX)
Monday, August 16, 2010 - 6:59pm | 164On CNBC's Fast Money, Joe Terranova said that he is a buyer of PAREXEL International Corporation (NASDAQ: PRXL). Parexel (PRXL) fell 0.05% today, and closed at $20.04. Karen Finerman likes Genzyme Corporation (NASDAQ: GENZ), and Steve Grasso prefers Altria Group, Inc. (NYSE: MO). He has been...
-
Arrowhead Reports Fiscal 2010 Third Quarter Financial Results
Thursday, August 12, 2010 - 4:12pm | 127Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 third quarter ended June 30, 2010. For the quarter ended June 30, 2010, Arrowhead reported revenue of $134,000, compared with $2.6 million in the quarter ended June 30, 2009. The prior period...
-
Goldman Reiterated Conviction List Buy On PAREXEL International (PRXL)
Thursday, August 12, 2010 - 8:54am | 196In a research report Goldman Sachs reiterates its Conviction List Buy on shares of PAREXEL International Corporation (NASDAQ: PRXL) and has a $33 price target as it believes the sell off in shares are overdone. In the research report Goldman writes, "During the 2Q CRO earnings season, our...
-
Parexel Growth 'Almost Certainly' Will Accelerate: Jefferies (PRXL)
Wednesday, August 11, 2010 - 4:26pm | 105Jefferies & Co. commented today that "Growth almost certainly will accelerate" for Parexel International Corporation (NASDAQ: PRXL). Jefferies maintains a Buy rating on the stock. Parexel reported FY4Q10 EPS of $0.32 on $295.3M in revenues, compared to consensus estimates of $0.30 on $298M....
-
Luminex Reiterated at Neutral - Analyst Blog
Wednesday, August 11, 2010 - 4:06pm | 448We reaffirm our Neutral recommendation on Luminex Corp. (LMNX) after assessing the company’s second-quarter fiscal 2010 results. The company produced a mixed bag in the quarter with profit plunging 27% year over year on account of higher costs and taxes. Adjusted earnings missed the Zacks Consensus...
-
Medivation Narrows Loss - Analyst Blog
Wednesday, August 11, 2010 - 7:05am | 910Medivation Inc. (MDVN) reported a loss of 21 cents per share in the second quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 29 cents. Lower expenses led to the narrower loss. Revenues for the quarter were $15.8 million, well below the Zacks...
-
Qiagen Beats by a Whisker - Analyst Blog
Wednesday, August 11, 2010 - 4:07am | 580Qiagen NV (QGEN) reported an adjusted EPS to 22 cents in the second quarter of 2010, surpassing the Zacks Consensus Estimate by a penny. EPS decreased 8.3% year-over-year from 24 cents. Results in the second quarter were adjusted for business integration, acquisition related and restructuring...